Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.
Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.
复制标题
DOI：
10.1371/journal.pntd.0009551
复制
发表时间：
2021-07
影响因子：
3.8
通讯作者：
Cuevas LE
中科院分区：
文献类型：
--
作者：
Savage HR;Santos VS;Edwards T;Giorgi E;Krishna S;Planche TD;Staines HM;Fitchett JRA;Kirwan DE;Cubas Atienzar AI;Clark DJ;Adams ER;Cuevas LE
感染SARS-CoV-2的个体会产生中和抗体。我们调查了感染后携带SARS-CoV-2中和抗体的个体比例，以及这一比例如何随选定的协变量变化。本系统综述和荟萃分析检查了感染后携带SARS-CoV-2中和抗体的个体比例，以及这些比例如何随选定的协变量变化。使用最大似然法的三个模型通过研究组、协变量和单独提取的数据评估这些比例（方案CRD42020208913）。共查明983份报告，并列入27份。使用>1:20滴度切断，中和抗体个体的合并（95%CI）比例为85.3%(83.5 ~ 86.9)，分别为83.9%（82.2 ~ 85.6）、70.2%（68.1 ~ 72.5）和54.2%(52.0 ~ 56.5)，滴度分别为>1:40、>1:80和>1:160。重症患者的滴度分别为>1:80、84.8%[80.0-89.2]、>1:160、74.4%[67.5-79.7]，高于轻症患者（分别为56.7%[49.9-62.9]和44.1%[37.3-50.6]），而在无症状感染者中最低（分别为28.6%[17.9-39.2]和10.0%[3.7-20.1]）。IgG和中和抗体水平相关性较差。85%已证实感染SARS-CoV-2的个体具有可检测到的中和抗体。这一比例因疾病严重程度、研究环境、感染时间和抗体测定方法而异。严重急性呼吸综合征冠状病毒-2 （SARS-CoV-2）引发适应性免疫反应，包括免疫球蛋白A、M和G和中和抗体。中和抗体被认为是功能性免疫和保护的标志。然而，并非所有确诊感染的个体都有可检测到的中和抗体。在本系统综述中，我们调查了前SARS-CoV-2感染个体产生中和抗体的比例，其滴度是否随疾病严重程度而变化，以及它们与免疫球蛋白g的相关性。我们发现，大约85%的SARS-CoV-2感染个体具有可检测到的中和抗体。这一比例在严重冠状病毒病患者中较高，在无症状感染者中较低。不同研究之间的差异反映了用于测量免疫球蛋白和中和抗体的方法范围广泛，并突出了测量SARS-CoV-2抗体的国际参考标准的必要性。
Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how this proportion varies with selected covariates. This systematic review and meta-analysis examined the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with selected covariates. Three models using the maximum likelihood method assessed these proportions by study group, covariates and individually extracted data (protocol CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled (95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5–86.9) using the titre cut off >1:20 and 83.9% (82.2–85.6), 70.2% (68.1–72.5) and 54.2% (52.0–56.5) with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0–89.2], >1:160, 74.4% [67.5–79.7]) than those with mild presentation (56.7% [49.9–62.9] and 44.1% [37.3–50.6], respectively) and lowest among asymptomatic infections (28.6% [17.9–39.2] and 10.0% [3.7–20.1], respectively). IgG and neutralising antibody levels correlated poorly. 85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibodies. This proportion varied with disease severity, study setting, time since infection and the method used to measure antibodies. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) elicits adaptive immunological responses, including immunoglobulins A, M, and G and neutralising antibodies. Neutralising antibodies are considered markers of functional immunity and protection. However, not all individuals with proven infections have detectable neutralising antibodies. In this systematic review, we investigated the proportion of individuals with former SARS-CoV-2 infections who develop neutralising antibodies, whether their titres vary with disease severity, and their correlation with Immunoglobulin G. We found that approximately 85% of individuals with SARS-CoV-2 infection have detectable neutralising antibodies. This proportion was higher among patients with severe Coronavirus Disease 19 and lower in asymptomatic infections. The variation across studies reflected the wide range of methods used to measure both immunoglobulins and neutralising antibodies, and highlight the need for an international reference standard to measure SARS-CoV-2 antibodies.
登录
查看更多内容
影响因子：
158.5
作者：
Li, Qun;Guan, Xuhua;Feng, Zijian
通讯作者：
Feng, Zijian
影响因子：
64.8
作者：
Gaebler C;Wang Z;Lorenzi JCC;Muecksch F;Finkin S;Tokuyama M;Cho A;Jankovic M;Schaefer-Babajew D;Oliveira TY;Cipolla M;Viant C;Barnes CO;Bram Y;Breton G;Hägglöf T;Mendoza P;Hurley A;Turroja M;Gordon K;Millard KG;Ramos V;Schmidt F;Weisblum Y;Jha D;Tankelevich M;Martinez-Delgado G;Yee J;Patel R;Dizon J;Unson-O'Brien C;Shimeliovich I;Robbiani DF;Zhao Z;Gazumyan A;Schwartz RE;Hatziioannou T;Bjorkman PJ;Mehandru S;Bieniasz PD;Caskey M;Nussenzweig MC
通讯作者：
Nussenzweig MC
影响因子：
12.7
作者：
Kohmer, Niko;Westhaus, Sandra;Rabenau, Holger F.
通讯作者：
Rabenau, Holger F.
影响因子：
11.1
作者：
Padoan A;Bonfante F;Pagliari M;Bortolami A;Negrini D;Zuin S;Bozzato D;Cosma C;Sciacovelli L;Plebani M
通讯作者：
Plebani M
影响因子：
64.8
作者：
Crackower, MA;Sarao, R;Penninger, JM
通讯作者：
Penninger, JM